<p>KEYMED BIO-B (02162.HK) announced its 2025 annual results, with revenue recorded at RMB 716 million, an increase of 67.3% year-on-year. The loss slightly widened from RMB 515 million in the previous year to RMB 523 million, with a loss per share of RMB 1.91. No final dividend will be distributed</p>

560600

516820

<p>KEYMED BIO-B announced its 2025 annual results, with revenue recorded at RMB 716 million, an increase of 67.3% year-on-year. The loss slightly widened from RMB 515 million in the previous year to RMB 523 million, with a loss per share of RMB 1.91. No final dividend will be distributed</p>

AASTOCKS

Founder Fubon CSI Medicine and Medical Device Innovation ETF

First Trust NYSE Arca Biotech Index Fd

Ping An CSI Medicine and Medical Device Innovation ETF

Tianhong CNI BIOMEDICINE ETF

China Merchants CSI Biotechnology Theme ETF

E Fund CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

China Southern Hang Seng Biotech ETF(QDII)

Guotai CSI Bio-medicine ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Penghua SSE STAR Biology and Medicine ETF

Minsheng Royal CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

ICBCCS SSE STAR Biology and Medicine ETF

KEYMED BIO-B

"Performance" KEYMED BIO-B's annual loss slightly widened to 523 million RMB